REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

REGENERON PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

01/10/2022 | 06:05am EDT

Item 2.02. Results of Operations and Financial Condition.

On January 10, 2022, at the virtual 40th Annual J.P. Morgan Healthcare Conference, Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron, are providing a corporate update.

The presentation includes information regarding the Company's preliminary (unaudited) U.S. net product sales of EYLEA® (aflibercept) Injection of approximately $5.79 billion for the full year 2021 (based on preliminary (unaudited) fourth quarter 2021 U.S. net product sales of EYLEA of approximately $1.54 billion).

The presentation also includes information regarding the Company's preliminary (unaudited) U.S. net product sales of REGEN-COV®(casirivimab and imdevimab) of approximately $5.82 billion for the full year 2021 (based on preliminary (unaudited) fourth quarter 2021 U.S. net product sales of REGEN-COV of approximately $2.29 billion).


Item 7.01.   Regulation FD Disclosure.


The information set forth under Item 2.02 of this Current Report on Form 8-K is incorporated by reference herein. A copy of the presentation referenced in Item 2.02 is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference in this Item 7.01.

The information included in Item 2.02 and the information included or incorporated in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits.



  99.1       Presentation by Leonard S. Schleifer, M.D., Ph.D., President and Chief
           Executive Officer of Regeneron Pharmaceuticals, Inc., and George D.
           Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of
           Regeneron Pharmaceuticals, Inc., at the virtual 40th Annual J.P. Morgan
           Healthcare Conference.

104        Cover Page Interactive Data File - the cover page XBRL tags are embedded
           within the Inline XBRL document.

© Edgar Online, source Glimpses

All news about REGENERON PHARMACEUTICALS, INC.
05/16Regeneron Pharmaceuticals, Inc. - HIGH SCHOOL SCIENTISTS FROM AROUND THE WORLD WIN NEAR..
AQ
05/13High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at ..
PR
05/13High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at ..
PR
05/10TRANSCRIPT : Regeneron Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare C..
CI
05/05RBC Capital Adjusts Regeneron Pharmaceuticals Price Target to $658 From $647, Maintains..
MT
05/04Regeneron's COVID drug sales outside U.S. help revenue beat
RE
05/04GLOBAL MARKETS LIVE : Airbnb, Pandora, Apple, Twitter, Meta...
05/04WALL STREET STOCK EXCHANGE : Finally, it's time for Powell's speech
05/04TRANSCRIPT : Regeneron Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04US Futures Higher Ahead of Fed Funds Rate Announcement, National Employment Report
MT
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 11 844 M - -
Net income 2022 4 040 M - -
Net cash 2022 8 716 M - -
P/E ratio 2022 17,6x
Yield 2022 -
Capitalization 70 575 M 70 575 M -
EV / Sales 2022 5,22x
EV / Sales 2023 4,73x
Nbr of Employees 10 492
Free-Float 81,0%
Chart REGENERON PHARMACEUTICALS, INC.
Duration : Period :
Regeneron Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 655,01 $
Average target price 689,35 $
Spread / Average Target 5,24%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS, INC.3.72%70 575
GILEAD SCIENCES, INC.-14.28%78 068
VERTEX PHARMACEUTICALS15.74%65 005
WUXI APPTEC CO., LTD.-16.67%42 275
BIONTECH SE-41.35%36 745
GENMAB A/S-19.81%19 313